Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL921259 | 0.93 | KMT2A (0.53) | MAPK8KMT2AKLKB1HPGD | |
| SCHEMBL920343 | 0.90 | KMT2A (0.61) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL12352268 | 0.89 | KMT2A (0.50) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL920670 | 0.89 | MAPK8 (0.53) | MAPK8KMT2AHPGDCYP3A4MAPK14 | |
| SCHEMBL920461 | 0.88 | MAPK8 (0.67) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL921271 | 0.87 | HPGD (0.57) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL921448 | 0.87 | MAPK8 (0.53) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL920714 | 0.87 | MAPK8 (0.53) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL920462 | 0.87 | MAPK8 (0.53) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL920561 | 0.87 | MAPK8 (0.53) | MAPK8KLKB1LMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101951771-A | Composition for agricultural use for controlling or preventing plant diseases caused by plant pathogens | SUMITOMO CHEMICAL CO | 2011-01-19 | — | — | CN | disclosed |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2248423-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | Sumitomo Chemical Company, Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009454-A1 | COMPOSITION FOR AGRICULTURAL USE FOR CONTROLLING OR PREVENTING PLANT DISEASES CAUSED BY PLANT PATHOGENS | WIZ, TST, NAT1 | MAPK8 2313/4885KMT2A 2469/4885HTR2C 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.